Multiple anti-inflammatory agents are thus currently undergoing clinical evaluation for COVID-19, including not only corticosteroids but also biologicals that target inflammatory cytokines, such as anti-IL-6 or anti-IL-1β agents, and other immune-modulatory agents (Table 1). The gene discussed is IL1B; the disease is COVID-19.